• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Root Jonathan D

    10/8/21 5:16:20 PM ET
    $LWAC
    Finance
    Get the next $LWAC alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    ROOT JONATHAN D

    (Last) (First) (Middle)
    C/O EFFECTOR THERAPEUTICS, INC.
    11120 ROSELLE ST SUITE A,

    (Street)
    SAN DIEGO CA 92121

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    eFFECTOR Therapeutics, Inc. [ EFTR ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    10/06/2021
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $11.36 10/06/2021 A 40,000 (1) 10/05/2031 Common Stock 40,000 $0.00 40,000 D
    Explanation of Responses:
    1. The shares subject to the option will vest in substantially equal monthly installments over three years, commencing on August 25, 2021, subject to the Reporting Person's continued service with the Issuer through each vesting date.
    Remarks:
    /s/ Michael Byrnes, Attorney-in-Fact for Jonathan D. Root 10/08/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $LWAC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LWAC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LWAC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Ehrlich Christopher B

      4 - eFFECTOR Therapeutics, Inc. (0001828522) (Issuer)

      10/8/21 5:22:23 PM ET
      $LWAC
      Finance
    • SEC Form 4 filed by Bhatt Elizabeth

      4 - eFFECTOR Therapeutics, Inc. (0001828522) (Issuer)

      10/8/21 5:20:18 PM ET
      $LWAC
      Finance
    • SEC Form 4 filed by Smither John W

      4 - eFFECTOR Therapeutics, Inc. (0001828522) (Issuer)

      10/8/21 5:18:52 PM ET
      $LWAC
      Finance

    $LWAC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Locust Walk Acquisition Corp.'s Stockholders Approve Business Combination with eFFECTOR Therapeutics to Create Next-Generation Oncology Company Developing New Class of Cancer Therapies

      SAN DIEGO, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Locust Walk Acquisition Corp. (NASDAQ:LWAC) ("LWAC" or the "Company"), a special purpose acquisition company, announced today that the Company's stockholders have approved all proposals related to the previously announced business combination (the "Business Combination") with eFFECTOR Therapeutics, Inc. ("eFFECTOR") at a special meeting of stockholders held on August 24, 2021. Approximately 93.2% of the votes cast at the meeting on the Business Combination proposal, representing approximately 71.7% of LWAC's outstanding shares, voted to approve the Business Combination. LWAC stockholders also voted overwhelmingly to approve the other proposals

      8/24/21 4:47:39 PM ET
      $LWAC
      Finance
    • eFFECTOR Therapeutics Initiates Phase 2a Expansion Cohorts Evaluating Zotatifin in Breast Cancer and KRAS-mutant Non-small Cell Lung Cancer

      SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (eFFECTOR), a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, announced today the initiation of dosing in the Phase 2a expansion portion of an ongoing Phase 1/2 trial of zotatifin (eFT226) in solid tumors. This followed conclusion of the Phase 1 dose escalation portion of the trial and selection of a recommended Phase 2 dose (RP2D). eFFECTOR expects to initiate multiple indication-specific expansion cohorts in ER+ breast cancer and KRAS-mutant non-small cell lung cancer (NSCLC). Zotatifin will be evaluated both as a single agent and in combination with targ

      8/4/21 8:00:00 AM ET
      $LWAC
      Finance
    • eFFECTOR Therapeutics Doses First Patient with COVID-19 in Phase 1b Clinical Trial Evaluating Zotatifin as a Host-Targeted Antiviral Agent

      SAN DIEGO, July 22, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, today announced that the first patient has been dosed in a Phase 1b trial evaluating zotatifin (eFT226) as an antiviral agent in an outpatient setting for those with mild to moderate COVID-19 disease. This study is sponsored by a $5.0 million cooperative agreement from the Defense Advanced Research Projects Agency (DARPA) and Defense Health Agency (DHA) and is being conducted in collaboration with the Quantitative Biosciences Institute (QBI) at University of California, San Francisco (UCSF). "Rising case

      7/22/21 8:00:00 AM ET
      $LWAC
      Finance

    $LWAC
    SEC Filings

    See more
    • Amendment: SEC Form S-1/A filed by Locust Walk Acquisition Corp.

      S-1/A - LightWave Acquisition Corp. (0002061379) (Filer)

      6/9/25 8:37:32 AM ET
      $LWAC
      Finance
    • SEC Form EFFECT filed by Locust Walk Acquisition Corp.

      EFFECT - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)

      10/6/21 12:15:17 AM ET
      $LWAC
      Finance
    • SEC Form 424B3 filed by Locust Walk Acquisition Corp.

      424B3 - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)

      10/5/21 4:24:26 PM ET
      $LWAC
      Finance

    $LWAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Locust Walk Acquisition Corp.

      SC 13D - eFFECTOR Therapeutics, Inc. (0001828522) (Subject)

      9/13/21 6:23:36 AM ET
      $LWAC
      Finance
    • SEC Form SC 13D filed by Locust Walk Acquisition Corp.

      SC 13D - eFFECTOR Therapeutics, Inc. (0001828522) (Subject)

      9/7/21 5:12:00 PM ET
      $LWAC
      Finance
    • SEC Form SC 13D filed by Locust Walk Acquisition Corp.

      SC 13D - eFFECTOR Therapeutics, Inc. (0001828522) (Subject)

      9/3/21 4:00:25 PM ET
      $LWAC
      Finance